There are three obstacles to faster development and deployment of non-addictive pain treatments. They are the business ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

The draft guidance, which is touted as a way to reduce the cost and time-associated burden of biosimilar development, has ...

Experts at SCOPE Europe 2025 confronted the challenges posed by rapid trial proliferation, digital transformation and ...

The purchase is expected to complement Thermo’s clinical research services, as companies are conducting more clinical trials.

The presentations will premiere at the time listed above and can be accessible by visiting the Presentation & Events section on the “Investors” page of Aligos’ website at www.aligos.com. A replay of ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and ...

Topline data from the chronic cohort is expected in Q2 2025 Institutional Review Board (IRB) protocol amendment changes approved, and screening has been initiated for subacute cohort This news release ...

Sai Life Sciences announces the groundbreaking of a state-of-the-art CMC Process R&D Center in Hyderabad, poised to double ...